Andros Pharmaceuticals Co., Ltd.

About Us

Shareholders

  • Everlight Chemical Industrial Corporation
  • Industrial Technology Investment Corporation
  • SinoPac Venture Capital Corp.
  • Other private investors
 

Management

Since the inception of Andros Pharma, Dr. Wang led a team of researchers from diverse backgrounds of pharmacy, chemistry, chemical engineering, and molecular biology, to create the core competency of Andros Pharma. Consultants including medical physicians, professors, and lawyers, play important roles in forming strategies in R&D and business development.
  • Ae-June Wang , President and CEO

    Dr. Ae-June Wang founded Andros Pharmaceuticals in 2008, and has been President and CEO since. Prior to Andros Pharma, she served as Vice President and Chief Science Officer at Purzer Pharmaceutical. She developed a topical liposomal product, first ever new dosage form approved in Taiwan. Before Purzer, she served as Senior Manager of Drug Delivery Department at ITRI, managing the GMP plant for transdermal patches. During her time at ITRI, she developed various innovative drug delivery technologies, which were subsequently transferred to domestic and foreign partners. Dr. Wang has over 50 patents, received numerous domestic and international awards, and has over 20 years of experience in drug development and management.

    Dr. Wang received Ph.D. in Analytical Biochemistry from the University of Iowa, and conducted postdoctoral research at the University of Hawaii. She received B.S. in Chemistry from Fu Jen Catholic University.

  • Chung-Kung Lai, Chief Operating Officer

    Dr. Chung-Kung Lai joined Andros Pharma in 2015 as Chief Operating Officer. Prior to Andros Pharma, he served as Professor of Chemistry and Director of General Affairs at the National Central University. At the National Central University, he has served as Deputy Director of Academic Affairs, Director of Environmental Protection and Safety, and Head of Chemistry Department. His research field ranges from organic and inorganic materials to specialized drug carriers. Dr. Lai has more than 100 publications and patents, and has over 20 years of combined experience in academics and management.

    Dr. Lai received Ph.D. in Chemistry from Michigan State University, and conducted postdoctoral research at University of Buffalo and University of Pennsylvania. He received B.S. in Chemistry from Fu Jen Catholic University.

  • Mei-Wen Yen, Director of Research and Development

    Dr. Mei-Wen Yen joined Andros Pharma in 2014 as the Director of Research and Development. Prior to Andros Pharma, she served as a Senior Manager at Dow Pharmaceutical Sciences, where she led the development of topical new drugs. Before joining Dow Pharmaceutical, She served as Principal Scientist at Altana, Nycomed, and Fougera, with extensive experience in drug analysis, formulation and process development. Before entering pharmaceutical industry, she was an Assistant Professor in Chemistry at Fordham University. Dr. Yen has over 20 years of experience in the development of new dosage form and generic drugs.

    Dr. Yen received Ph.D. in Chemistry from State University of New York (SUNY) at Stony Brook and B.S. in Chemistry from National Taiwan Normal University.

  • Herbert Shih, Director of Business Development

    Mr. Herbert Shih joined Andros Pharma in 2017 as the Director of Business Development. Prior to Andros Pharma, he served as the General Manager at Phoebus Biopharm, Vice President of Rosetta Pharmamate, Marketing Manager of Roche Pharmaceuticals, Product Manager and Regulatory Affairs Manager at AstraZeneca, where he was in charge of marketing various well-known pharmaceutical products. Mr. Shih is a certified pharmacist, with dual master's degrees in management and law, and has over 20 years of experience in pharmaceutical marketing and management.

    Mr. Shih received MBA from the University of Leicester, LLM from Shih Hsin University, and B.S. in Pharmacy from Taipei Medical University.

  • Shu-Min Ni, Senior Manager of Finance and Administration

    Ms. Shu-Min Ni joined Andros Pharma in 2012. She has been serving as Assistant Manager, Manager, and was recently promoted to Senior Manager of Finance and Administration. Prior to Andros Pharma, she served as Deputy Chief of Accounting at Shin-Etsu Handotai Taiwan. Before that, at an accounting firm, she was in charge of companies’ public offering and listing. Ms. Ni has over 18 years of experience in financial accounting, auditing, and administration.

    Ms. Ni received Bachelor of Accountancy from Chinese Cultural University.